Tsu-Yao Cheng

Tsu-Yao Cheng

Auto-generated profile, based on publicly available information

Tsu-Yao Cheng

Division of Gastroenterology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan; Department of Laboratory Medicine, National Taiwan University College of Medicine, Taiwan

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2010 in Cancer Research
Verified
Journal Article
Closed access
PDF file
MCMin-Wei Chen
Min-Wei Chen
KHKuo-Tai Hua
Kuo-Tai Hua
HKHsin-Jung Kao
Hsin-Jung Kao
CCChia-Chun Chi
Chia-Chun Chi
LWLin-Hung Wei
Lin-Hung Wei
MKMin-Liang Kuo
Min-Liang Kuo
G9a is a mammalian histone methyltransferase that contributes to the epigenetic silencing of tumor suppressor genes. Emerging evidence suggests that G9a is required to maintain the malignant phenotype, but the role of G9a function in mediating tumor metastasis has not been explored. Here, we show that G9a is expressed in aggressive lung cancer cells, and its elevated expression correlates with poor prognosis. RNAi-mediated knockdown of G9a in highly invasive lung cancer cells inhibited cell migration and invasion in vitro and metastasis in vivo. Conversely, ectopic G9a expression in weakly invasive lung cancer cells increased motility and metastasis. Mechanistic investigations suggested that repression of the cell adhesion molecule Ep-CAM mediated the effects of G9a. First, RNAi-mediated knockdown of Ep-CAM partially relieved metastasis suppression imposed by G9a suppression. Second, an inverse correlation between G9a and Ep-CAM expression existed in primary lung cancer. Third, Ep-CAM repression was associated with promoter methylation and an enrichment for dimethylated histone H3K9. G9a knockdown reduced the levels of H3K9 dimethylation and decreased the recruitment of the transcriptional cofactors HP1, DNMT1, and HDAC1 to the Ep-CAM promoter. Our findings establish a functional contribution of G9a overexpression with concomitant dysregulation of epigenetic pathways in lung cancer progression. Cancer Res; 70(20); 7830–40. ©2010 AACR.

28 April 2010 in Gut
Verified
Journal Article
Closed access
PDF file
JLJyh-Ming Liou
Jyh-Ming Liou
JLJaw-Town Lin
Jaw-Town Lin
CCChi-Yang Chang
Chi-Yang Chang
MCMei-Jyh Chen
Mei-Jyh Chen
TCTsu-Yao Cheng
Tsu-Yao Cheng
MWMing-Shiang Wu
Ming-Shiang Wu
Background: The efficacy of a levofloxacin-based regimen as the first-line treatment and a clarithromycin-based regimen as the second-line treatment for Helicobacter pylori infection remains unknown. The aim of this study was to assess the eradication rates of these two regimens using different administration sequences. Methods: Eligible patients were randomised to receive LAL: levofloxacin (750 mg once a day), amoxicillin (1000 mg twice a day) and lansoprazole (30 mg twice a day) for 7 days, or CAL: clarithromycin (500 mg twice a day), amoxicillin (1000 mg twice a day) and lansoprazole (30 mg twice a day) for 7 days. Patients with positive [13C]urea breath test after treatment were retreated with the rescue regimen in a crossover manner for 10 days. Result: When used as first-line treatment (n=432), the eradication rates of LAL (n=217) and CAL (n=215) were 74.2 and 83.7% (p=0.015) in the intent-to-treat (ITT) analysis, and 80.1 and 87.4% (p=0.046) in the per-protocol (PP) analysis, respectively. When used as second-line treatment, the eradication rates of LAL (n=26) and CAL (n=40) were 76.9 and 60% (p=0.154) in the ITT analysis, and 80 and 61.5% (p=0.120) in the PP analysis, respectively. The overall eradication rates of CAL followed by LAL were better than the reverse sequence in both the ITT analysis (93% vs 85.3%, p=0.01) and the PP analysis (97.6% vs 92.5%, p=0.019). The eradication rate was significantly lower in the presence of levofloxacin resistance in the LAL group (50% vs 84.4%, p=0.018) and clarithromycin resistance in the CAL group (44.4% vs 90.7%, p=0.002). Conclusion: CAL achieved a higher eradication rate than LAL as the first-line treatment, but not as the second-line treatment. The strategy of using CAL as the initial treatment and LAL as the rescue regimen achieved higher eradication rates than the reverse sequence. Clinical trial number NCT00816140.

26 June 2012 in Cancer
Verified
Journal Article
Open access
PDF file
TCTsu‐Yao Cheng
Tsu‐Yao Cheng
MWMing-Shiang Wu
Ming-Shiang Wu
JLJaw‐Town Lin
Jaw‐Town Lin
MLMING-TSAN LIN
MING-TSAN LIN
CSChia-Tung Shun
Chia-Tung Shun
MKMin‐Liang Kuo
Min‐Liang Kuo
BACKGROUND: Annexin A1 (AnxA1) has been well‐known as a glucocorticoid‐regulated anti‐inflammatory protein, and it is implicated in tumorigenesis in a tumor type–specific pattern. However, the role of AnxA1 in gastric cancer (GC) is indeterminate, and the underlying mechanism is not clear. The purpose of this study was to evaluate the prognostic significance and associated mechanism of AnxA1 in GC.METHODS: Immunohistochemical staining was employed to analyze 118 GC patients. Both AnxA1 gain‐of‐function and loss‐of‐function approaches were performed in GC cells. Western blotting and reverse‐transcription polymerase chain reaction were used for assessment of the AnxA1 regulation mechanism in GC cells. An intraperitoneal inoculation model in severe combined immunodeficient mice was used for an in vivo assay.RESULTS: High AnxA1 expression was significantly associated with peritoneal metastasis (P = .009) and serosal invasion (P = .044). Cox multivariate analysis showed that high AnxA1 expression was an independent risk factor for poor overall survival in GC patients (P = .037). AnxA1 expression positively correlated with invasiveness of human GC cells both in vitro and in vivo. AnxA1 could regulate the GC cell invasion through the formyl peptide receptor (FPR)/extracellular signal‐regulated kinase/integrin beta‐1‐binding protein pathway, and all 3 FPRs (FPR1 through FPR3) were involved in the regulation process.CONCLUSIONS: High AnxA1 expression was associated with more serosal invasion, more peritoneal metastasis, and poorer overall survival in GC patients. The current study demonstrated a novel mechanism involving FPRs, extracellular signal‐regulated kinases 1 and 2, and integrin beta‐1‐binding protein 1 by which AnxA1 regulated GC cell invasion. Cancer 2012. © 2012 American Cancer Society.

1 February 2011 in Cancer Cell
Verified
Journal Article
Closed access
KHKuo-Tai Hua
Kuo-Tai Hua
CTChing-Ting Tan
Ching-Ting Tan
GJGunnar Johansson
Gunnar Johansson
JLJang-Ming Lee
Jang-Ming Lee
PYPei-Wen Yang
Pei-Wen Yang
MKMin-Liang Kuo
Min-Liang Kuo

1 October 2018 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
JLJyh-Ming Liou
Jyh-Ming Liou
PCPo-Yueh Chen
Po-Yueh Chen
JLJiing-Chyuan Luo
Jiing-Chyuan Luo
JLJi-Yuh Lee
Ji-Yuh Lee
CCChieh-Chang Chen
Chieh-Chang Chen
WCWen-Shiung Chang
Wen-Shiung Chang

20 July 2006 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
TCTsu-Yao Cheng
Tsu-Yao Cheng
JLJaw-Town Lin
Jaw-Town Lin
LCLi-Tzong Chen
Li-Tzong Chen
CSChia-Tung Shun
Chia-Tung Shun
HWHsiu-Po Wang
Hsiu-Po Wang
MWMing-Shiang Wu
Ming-Shiang Wu
Purpose: Helicobacter pylori infection and host susceptibility interact to develop gastric mucosa-associated lymphoid tissue (MALT) lymphoma, and activation of specific T cells might play a crucial role in this process. Recent investigations show that the CTLA4, CD28, and ICOS genes are located on chromosome 2q33 and their polymorphisms confer susceptibility to infectious and immune diseases through deregulation of T-cell stimulation. We aimed to determine the role of CTLA4, CD28, and ICOS polymorphisms in gastric MALT lymphoma. Patients and Methods: Genotyping for CTLA4 (49 A/G, −318 C/T, and CT60 A/G), CD28 (IVS3+ 17T/C), and ICOS (c.602 A/C and c.1624C/T) was performed for 62 patients with gastric MALT lymphoma and compared with 250 unrelated healthy controls. Results: H pylori infection was significantly higher in patients with gastric MALT lymphoma (90.3%) compared with controls (66.4%; P < .001). The CTLA4 −318 C/T genotype was associated with a lower risk of developing gastric MALT lymphoma (odds ratio [OR] = 0.3; P = .022), whereas CTLA4 49 G/G genotype was linked to a higher risk (OR = 4.1; P = .044). In patients with H pylori infection, CTLA4 49 G/G genotype was associated with an even higher risk (OR = 6.4; P = .047). Carriage of the tightly linked −318C –49G haplotype conferred a four-fold higher susceptibility to MALT lymphoma (OR = 4.2; P = .042). Complete remission after H pylori eradication was related to tumor stage but not to genotypes or haplotypes. Conclusion: These results indicate a genetic link of CTLA4 gene polymorphisms to development of gastric MALT lymphoma and indirectly support the crucial role of host activated T cells in the MALT lymphomagenesis.